Edwards Lifesciences vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Edwards Lifesciences Corp (EW)

Q3 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

August 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Latest30 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.